Type
Internal restructuring
Country
France
Region
Auvergne-Rhône-Alpes; Rhône-Alpes; Rhône
Location of affected unit(s)
Lyon
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.20 - Manufacture of pharmaceutical preparations

146 jobs
Number of planned job losses
Job loss
Announcement Date
4 November 2025
Employment effect (start)
4 November 2025
Foreseen end date

Description

Boehringer Ingelheim, the German pharmaceutical company, is cutting 146 jobs in the Rhône region. The majority of the job losse will affect the Gerland site in Lyon. According to the FO trade union, the company has not been transparent since the takeover of the health department of Sanofi in 2018. A previous job-saving plan was implemented in 2022. The restructuring appears to due to a lack of investment in production sites, as well as the impact of restructuring on productivity and skill loss. The trade union Force Ouvrière has reacted strongly, demanding that no layoffs occur and urging the company to invest in the site.

Several large restructurings have been recorded in the ERM database, with around to 327 to 507 job cuts in 2018 Boehringer Ingelheim France 2018 - FR


Sources

Citation

Eurofound (2025), Boehringer-Ingelgeim France, Internal restructuring in France, factsheet number 203623, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/203623.